Additionally, we identified that DNA damage repair‐related drugs such as Bleomycin and Gemcitabine; EGFR inhibitors such as Lapatinib and Pazopanib; PI3K/mTOR inhibitors such as Rapamycin, Shikonin, and temsirolimus; Bcl‐2 inhibitors such as Obatoclax and TW.37; as well as MEK inhibitors such as CI.1040 and RDEA119 with relatively lower IC50 values might also be treatment options for high‐risk CC patients. The gene discussed is MAP2K7; the disease is cholangiocarcinoma.